Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of the HER2 receptor, and lapatinib, a dual reversible EGFR/HER2 TKI, are indicated for the treatment of HER2 ...

(Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

The results suggest that AZ and Daiichi Sankyo could be in line for a second big win for a cancer ADC to follow Enhertu (trastuzumab deruxtecan), their HER2-directed drug which has just claimed a ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...